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Introduction
At physiological pH about 40% of all prescribed drugs are cationic (Ahlin, et al., 2008; Neuhoff, et al., 2003) and these 'organic cations' (OCs) are potential substrates for one or more of the transport processes that mediate renal secretion of endogenous and exogenous OCs.
The latter group includes many commonly prescribed drugs and, consequently, OC transport influences their pharmacokinetic and pharmacodynamic profiles. The existence within the kidney of a common pathway(s) for the secretion of OCs (cimetidine, trimethoprim, metformin, etc.) sets the stage for unwanted drug-drug interactions (DDIs) (Endres, et al., 2006) . In addition, genetic variation of drug transporters has been linked to inter-individual variation in drug efficacy, toxicity, and pharmacokinetics (Sissung, et al., 2012) . The clinical cost of DDIs is substantial and responsible for about 1% of hospital admissions (almost 5% in elderly populations) (Becker, et al., 2007; U.S.Food and Drug Administration, 2012b) , so the ability to predict potential DDIs is a commendable goal.
In the human kidney the initial step in renal OC secretion, i.e., entry of substrate from the blood into renal proximal tubule cells, appears to be dominated by activity of the organic cation transporter homolog, OCT2 (Motohashi, et al., 2002) . Its central role in this process has made OCT2 a focal point for efforts to develop predictive models of substrate/inhibitor binding to the transport protein. Models of the interaction of ligands (incl. substrates and inhibitors) with OCT2 (Suhre, et al., 2005; Kido, et al., 2011; Zolk, et al., 2009) , as well as the models of ligand interaction with its hepatic homolog, OCT1 (Bednarczyk, et al., 2003; Ahlin, et al., 2008; Moaddel, et al., 2007) , typically identify 'charge' and some measure of 'hydrophobicity' as key determinants of ligand binding (see also (Ullrich, 1997) ). However, the several 3D pharmacophores that have attempted to highlight the molecular determinants of ligand-transport JPET #203257 page 5 interaction (Bednarczyk, et al., 2003; Moaddel, et al., 2007; Zolk, et al., 2009; Suhre, et al., 2005) display similar but structurally distinct placements of 'hydrophobes,' 'cationic features,' and hydrogen bond donor/acceptor sites. Whereas the bases of these discrepancies could include methodological and/or analytical differences between these studies, we suggest another, generally unacknowledged complicating factor, namely the influence of 'substrate' on OCT interaction with an 'inhibitor.' In this regard, it is interesting that the three modeling efforts with OCT2 (and the three with OCT1) were based on profiles of inhibition of structurally distinct substrates: 1-methyl-4-phenylpyridinium (MPP) (Moaddel, et al., 2007; Zolk, et al., 2009 ), tetraethylammonium (TEA) (Bednarczyk, et al., 2003; Suhre, et al., 2005) , or 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP + ) (Ahlin, et al., 2008; Kido, et al., 2011) produced by inhibitory ligands. Thus, the differences in the resulting models, noted earlier, may have reflected, at least to some degree, 'substrate-dependent' ligand inhibition of these processes.
An influence of substrate on the profile of ligand interaction has been noted for other multidrug transporters, including P-glycoprotein (Garrigues, et al., 2002; Ekins, et al., 2002) and the organic anion transporting polypeptides (Roth, et al., 2011; Westholm, et al., 2009) . In their extensive review of the literature, Nies et al. (2011) compiled the inhibitory profiles for a 100+ inhibitory ligands against transport activity of human OCT2 (as well as OCT1, OCT3, MATE1
and MATE2-K). Noting variation in IC 50 values that were often associated with differences in probe substrate, they suggested: "The existence of various substrate and inhibitor binding sites (as discussed by Nies et al. (2011) ), so to are there multiple examples of similar degrees of variance in kinetic constants when different studies report IC 50 values for inhibition of transport of the same substrate by the same test inhibitor (cf. Nies et al., (2011) ). Consequently, it is difficult to draw conclusions on the issue of substrate-dependent ligand interactions based on data generated by different groups. However, a recent study by Zolk et al. (2009) provided a set of observations that warrants discussion. They compared IC 50 values for seven structurally distinct cationic drugs against OCT2-mediated transport of MPP and metformin. Lending particular credence to the idea that substrate identity may influence interaction of inhibitory ligands with OCT2, their rersults showed that each test compound was a more effective (~10-fold) inhibitor of metformin than of MPP.
In the present study we test the hypothesis that the effectiveness of cationic drugs as inhibitors of OCT2 can be significantly influenced by the substrate used in the transport assay.
We confirmed the observation of Zolk et al. (2009) (Aavula, et al., 2006 American Radiochemicals) in benzene (200 µl) was added to amine 1 (see Fig. 1 in (Aavula, et al., 2006) ) (1.0 mg, 3.7 µmol); the mixture was contained in a clean, conical, heavy-walled glass vial (3 ml) and the vial sealed with a polytetrafluoroethylene (PTFE) lined screw-cap. The vial was kept in a secondary container (glass bottle) within a tertiary container (glass bottle) along with a piece of filter paper. The mixture was stirred for 3 weeks at room temperature. The filter This article has not been copyedited and formatted. The final version may differ from this version. paper was then checked for radioactivity, which was found to be negligible. The reaction vial was then cooled to about 5 ºC and a mixture of water (0.5 ml) and ethyl acetate (0.5 ml) was added. After careful mixing, the aqueous layer was removed using a gas-tight syringe. The aqueous layer was subjected to additional washing with ethyl acetate (2 x 0.5 ml). The aqueous solution was then assayed for radioactivity and was found to contain 27.3 mCi of the desired salt (138.8 µg, 0.34 µmol, 88%). Analysis by paper chromatography showed that the compound was >90% pure. Nutrient Mixture with 10% fetal bovine serum and supplemented with 100 µg/ml Zeocin. HEK 293 cells were grown in DMEM with 10% fetal bovine serum with 100 μ g/ml blasticidin. Cells that stably expressed OCT2 were prepared using methods described previously (Pelis, et al., 2007) . The OCT2-expressing cells were grown and maintained under hygromycin pressure (100 µg/ml) in plastic cell culture flasks at 37°C in a humidified atmosphere with 5% CO 2 . Cells were passed every 3-4 days and seeded into 48-well plates at 137,500 cells/well and typically used 48 hours later. 
Results
Kinetics of MPP transport -We routinely use CHO cells as an expression system to study OCT2 transport (e.g., (Pelis, et al., 2012; Harper and Wright, 2012; Pelis, et al., 2007; Suhre, et al., 2005) ). However, it is more common to use HEK 293 cells as an expression for studying OCTmediated transport (Nies, et al., 2011) . In the present study we compare data obtained using ligand (and OCT2 substrate) metformin (refer to Fig. 4 transport determined using our methods to those reported for the same compounds by Zolk et al. (2009) . These data are presented in Figure 2 as the log of our values versus the log of those reported by Zolk et al. (Fig. 2 ; Table 1 ). Only one of the compounds, chloroquine (the filled circle in Fig. 2 Figure   3A is a redrawing of data from the study by Zolk et al. (2009) 
Kinetic profiles of ligand inhibition of OCT2-mediated transport of MPP and metformin -
Ligand inhibition of OCT2-mediated transport of the fluorescent cation, NBD-MTMA -To
determine if substrate-dependence of inhibitory ligand interaction with OCT2 may be a general phenomenon (rather than restricted to MPP and metformin) we determined the profile of inhibition of OCT2-mediated transport of a structurally distinct substrate. We also took this opportunity to introduce to this type of work a novel OCT substrate with optical (i.e., fluorescent) properties that may prove useful for high throughput applications. Some years ago we described the synthesis of a novel fluorescent compound, [2-(4-nitro-2,1,3-benzoxadiazol-7-yl)aminoethyl]trimethylammonium ('NBD-TMA') and its use as a substrate of basolateral OC transport into isolated, single, non-perfused renal proximal tubules (Bednarczyk, et al., 2000) .
We subsequently reported (Aavula, et al., 2006 ) synthesis of a modest structural variation of NBD-TMA that both eliminated the modest pH-sensitivity of NBD-TMA and shifted the excitation and emission peaks of the resulting compound, 'NBD-MTMA' (Fig. 4) radiotracer-labeled NBD-MTMA and (ii) accumulated radioactivity. As shown in Figure 6D , the experimentally determined kinetics of OCT2-mediated NBD-MTMA transport were not influenced by the means of assessing the rate of uptake, i.e., the kinetic parameters based on uptake of fluorescence (K t of 9.0 ± 3.0 μ M and J max of 6.8 ± 0.7 pmol cm -2 min -1 ) were not different from those determined from uptake of radiolabeled substrate (K t of 9.6 ± 3.8 μ M and J max of 5.4 ± 0.6 pmol cm -2 min -1 ).
The IC 50 values for inhibition of OCT2-mediated NBD-MTMA transport produced by 22 inhibitory ligands are listed in Table 2 . These values spanned more than 3-orders of magnitude, with ipratropium displaying that highest apparent affinity for OCT2 (IC 50 of 170 nM), and metformin the lowest (1.2 mM) (Fig. 7) . Figure 8A (Segel, 1975) . However, in the experiments that generated the data in Table 2 the concentration of NBD-MTMA 'substrate' was 10 μ M, essentially equal to its K t value (Fig. 6D) . Consequently, in the event that the interaction of NBD-MTMA with an inhibitory ligand was competitive, the resulting 'IC 50 ' value is likely to overestimate actual 'K i ' value by about 2-fold (non-competitive and mixed type interactions would be less affected by the comparatively high concentration of substrate; (Segel, 1975) ). Thus, the difference in inhibitory efficacy of the test inhibitory ligands when blocking NBD-MTMA vs. MPP transport is likely to be even greater than indicated in Figure 8A . Figure   8B shows the ratio of (measured) IC 50 values for the test inhibitory ligands against the two substrates and emphasizes that the degree of deviation from identical IC 50 values was not a constant; it varied from a 3-fold difference toward more effective inhibition of MPP (metformin), to an 88-fold difference toward more effective inhibition of NBD-MTMA (ipratropium). Figure   9 shows the relationship between the (measured) IC 50 values for inhibition of OCT2-mediated 
Discussion
The results presented here support two broad conclusions. First, the profile of inhibition of OCT2 activity is both quantitatively and qualitatively influenced by the choice of substrate used to assess transport. Specifically, OCT2-mediated metformin transport was about 10-times more sensitive to inhibition by a structurally diverse array of cationic drugs than was OCT2-mediated transport of MPP; transport of the structurally distinct OCT2-substrate, NBD-MTMA, displayed an intermediate sensitivity to these inhibitory ligands, i.e., less sensitive to inhibition than transport of metformin, but more sensitive than transport of MPP. The resulting 'substrate dependence' of drug inhibition of OCT2 transport activity, which we suggest is likely to be true With respect to the latter point, the simplest model, arguably, of OC interaction with OCT2 involves competition for a common binding 'site,' or with sites that, while spatially distinct, overlap sufficiently to render their occupancy to be mutually exclusive. In the absence of contrary evidence it is frequently assumed, either explicitly (e.g., Tahara, et al., 2005; Amphoux, et al., 2006) or implicitly (e.g., Muller, et al., 2005) (Segel, 1975) .
Consequently, the evidence presented here showing that inhibitory ligands routinely displayed higher IC 50 values for inhibition of MPP than for either metformin or NBD-MTMA argues that these compounds ('inhibitors' and 'substrates') cannot interact with a common (or mutually exclusive set of) binding site(s). In retrospect, this is not a surprising observation. The hallmark 'multisubstrate specificity' (Ullrich, 1997) of renal OC transporters makes it difficult to reconcile the structural diversity of molecules like MPP and NBD-MTMA (Fig. 4) , and the observation that the apparent affinity of OCT2 for both is quantitatively similar (K t s of 9 shows a clear 'substrate-dependency' (e.g., Garrigues, et al., 2002; Ekins, et al., 2002) , as does the interaction of selected inhibitors with OATP-mediated transport (Roth, et al., 2011; Westholm, et al., 2009 ). Moreover, x-ray crystal structures of P-gp (Aller, et al., 2009 ) and the multidrug-binding transcription regulator, QacR (Schumacher and Brennan, 2003) reveal the presence of multisite binding pockets. With respect to the OCTs, a number of studies have suggested that inhibitors of OCT transport display 'allosteric' interactions at multiple sites (e.g., Egenberger, et al., 2012; Volk, et al., 2009; Minuesa, et al., 2009; Popp, et al., 2005; Volk, et al., 2003; Lee, et al., 2009 hydrophilic 'translocation pathway' suspected to exist with OCT1 (Popp, et al., 2005) and OCT2 (Zhang, et al., 2005; Pelis, et al., 2006) . Mutation of a single residue in rOct1 (D475E) exerts a profound effect on the affinity of the transporter for TEA and choline while having no effect on the kinetics of MPP transport (Gorboulev, et al., 1999) . Similarly, changing residue 447 in OCT2 (which imparts the marked difference in selectivity of OCT1 vs. OCT2 for cimetidine) from glutamate to leucine effectively eliminates transport of TEA and cimetidine but has no effect on MPP transport (Zhang, et al., 2005) , and mutation of C474 (adjacent to the aforementioned D475) markedly influences the apparent affinity of OCT2 for MPP but not TEA (Pelis, et al., 2012) . Taken with the observations reported here, the results of these studies support the hypothesis that OCTs have multiple, spatially distinct, binding sites within a large poly-specific substrate binding pocket.
Insight into structural features that may influence spatially distinct ligand interaction with MATE1 may be found by comparing the structures of the three probe substrates. Of the three, metformin stands out in the absence of an aromatic feature (Fig. 4) . With this in mind, it is interesting that the tested inhibitory ligands were generally more effective inhibitors of metformin transport than of MPP and NBD-MTMA transport, both of which posses multiple ring structures. The absence of an aromatic feature in metformin, and the generally stronger effectiveness of the tested ligands as inhibitors of MATE1-mediated metformin transport, suggests the presence of an alternative binding site that is not shared by MPP or NBD-MTMA.
In light of the evidence that profiles of ligand inhibition of OCT-mediated transport are influenced, both qualitatively and quantitatively, by choice of substrate (e.g., Fig. 8 ), the 'universality' of pharmacophores based on inhibition of a single substrate must be called into question. It may also explain the differences in principal features identified in studies using different probe substrates. For example, we previously described a pharmacophore, based on OCT2-mediated TEA transport, that was characterized by (i) a positive charge feature and (ii) a single hydrogen bond acceptor feature (Suhre, et al., 2005 ), whereas the model described by Zolk et al. (2009) , which was based of OCT2-mediated MPP transport, was characterized by (i) an ion interaction site and (ii) a hydrophobic (aromatic ring) site. As noted earlier, these differences may well have been influenced by the composition of the respective training sets and/or the analytical methods used for pharmacophore generation (Catalyst v 4.9 vs. LigandScout v 1.03).
However, interaction of MPP and TEA with OCT2 is 'mixed type' rather than competitive (Harper and Wright, 2012) , consistent with their interaction, both with each other and with other inhibitory ligands, at spatially distinct sites. We suggest that adequate description of ligand binding to OCT2 will require identification of a suitable cohort of structurally distinct probe substrates, as well as a structurally rich set of training inhibitors, to adequately explore the chemical space available for substrate/inhibitor interaction.
In addition to the influence that 'substrate-dependent' inhibition of OCT2 has on understanding the molecular basis of drug interaction with this transporter, it also has a marked impact on the use of defined protocols ('Decision Trees') designed to indentify potentials DDIs with OCTs, as well as other multidrug transporters, the results of which influence key decisions on the clinical and commercial future of these compounds (Giacomini, et al., 2010; Lepist and Ray, 2012) . For example, the current recommended guidance for initiating a clinical study of a drug's potential for DDI with OCT1 or OCT2 is a value of >0.1 for the ratio of 'unbound C max '
to the drug's IC 50 for inhibition of transport of MPP, the prototypic OCT substrate (Giacomini, et al., 2010 ;U.S.Food and Drug Administration, 2012a). Now consider: imipramine, a tricyclic antidepressant, has an unbound C max of 70 nM (Thummel and Shen, 2001) , and an IC 50 of 7 µM This article has not been copyedited and formatted. The final version may differ from this version. against OCT2-mediated MPP transport (Zolk, et al., 2009 ), resulting in a C max /IC 50 ratio of 0.01, well below the guidance limit. However, imipramine's IC 50 against OCT2-mediated metformin transport (determined in the same study; (Zolk, et al., 2009) ) is 0.4 µM, resulting in a ratio of 0.18, which would argue for a clinical DDI study (Giacomini, et al., 2010 ;U.S.Food and Drug Administration, 2012a). We suggest that the decision making process be more fully informed of a 'substrate-dependence' for inhibitor interaction with OCTs that appears to be the rule, rather than the exception.
In summary, structurally diverse cationic drugs were generally about 10-times more effective inhibitors of OCT2-mediated metformin transport than of MPP transport. A substratedependent inhibition profile was also seen for transport of the novel fluorescent cation, NBD-MTMA; test drugs were generally less effective inhibitors of NBD-MTMA than metformin, but more effective than MPP. These results suggest that substrate-dependent inhibitory ligand interaction is a common characteristic for OCT2. The results also argue for the presence within the translocation pathway of this multidrug transporter of a structurally complex binding surface than can accommodate ligand interactions with spatially distinct sites. Development of predictive models of drug interaction with OCT2 should acknowledge the need to consider interaction profiles with structurally distinct substrates. Decision Tree protocols for assessing the potential for DDIs between new and existing drugs must acknowledge that weak interaction between a test compound and one probe substrate may mask a more potent interaction with others.
This article has not been copyedited and formatted. The final version may differ from this version. Table 1 ) and those reported in Table 1 Table 1 in the present report) and MPP (y-axis; as reported in Table 1 Table 1 Comparison of IC 50 values for inhibition of OCT2 mediated MPP transport in the present study (column A) or in the study of Zolk et al. (2009) Table 2 Comparison of IC 50 values for inhibition of OCT2 mediated NBD transport (column A) or of OCT2-mediated transport of MPP (column B).
a Numbers represent the mean (±SE) of the number of separate experiments, performed OCT2-expressing CHO cells, indicated in parentheses.
b The values were obtained from Table 1 in Zolk et al. (2009 Table 3 Comparison of IC 50 values for inhibition of OCT2 mediated NBD-MTMA transport (column A) or of OCT2-mediated transport of metformin (Met) determined in the present study (column B), or the study by Zolk et al. (2009) 
